CELC - Celcuity LLC logo

Celcuity LLC

CELC

Celcuity LLC develops targeted therapies for solid tumors, focusing on advanced breast cancer and metastatic castration-resistant prostate cancer. Its lead drug, Gedatolisib, inhibits the PI3K/mTOR pathway and is in clinical trials for various indications.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 5 years ago โ†’$3,720today

Score Overview

1 Year
Score
Net Growth-8.95%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth0.00%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-4x
Net TrendNever
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend20%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-28x
Net Trend11%
Net Income Consistency
Rev Growthโ€”
Rev Trend11%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Celcuity LLC has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CELC does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 65.25โ€”
1 Year2025-10-23
$ 70.57-7.54%
5 Years2021-10-22
$ 17.54272.01%
All Time2017-09-20
$ 14.29356.61%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 154K-$ 192M$ 145M
2025$ 154K-$ 177M$ 441M
2024$ 0.00-$ 111M$ 235M
2023$ 0.00-$ 63M$ 180M
2022$ 0.00-$ 40M$ 168M
2021$ 0.00-$ 29M$ 84M
2020$ 0.00-$ 9M$ 11M
2019$ 0.00-$ 7M$ 18M
2018$ 0.00-$ 7M$ 24M
IPO2017$ 0.00-$ 6M$ 24M
CELC - Celcuity LLC logo

Celcuity LLC fundamental performance

Across Celcuity LLC's full reported history, from 2017 to 2025, revenue grew from $ 0.00 to $ 154K and net income went from -$ 6M to -$ 177M. Revenue increased in 11% of the years measured; net income in 11%.

Membership

Explore CELC with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies